Drug profile

The FDA adverse-event record for Emodepside,Praziquantel

18 FDA reports name Emodepside,Praziquantel, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#1903 of 2,679
by report volume (all drugs)
18
adverse-event reports
11.1%
death-coded share
Cat
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Emodepside,Praziquantel ranks #1884 of 2679 by total reports (18). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1884
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Emodepside,Praziquantel has 18 reports now versus 13 in that prior snapshot: 5 more (38.5%).

Report change
+5
Death-coded reports
+1
Death-coded share
+3.4 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Emodepside,Praziquantel changes

Signature read: 18 reports place Emodepside,Praziquantel in the lower third of FDA AER volume (#1903 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
18
Total Reports
2
Deaths Reported
11.1%
Death-coded share of reports

Active Ingredients

Emodepside,Praziquantel

Administration Routes

TopicalOral

Species Affected

Cat 18

Most Affected Breeds

Domestic Shorthair 14
Domestic Longhair 4

Most Reported Reactions

Lack of efficacy (endoparasite) - tapeworm 6
Hiding 3
Application site alopecia 2
Pinnae disorder 2
Straining to defecate 2
Constipation 2
Hind limb ataxia 2
Hard stool 2
Uncomfortable 2
Painful defecation 2
Limb weakness 2
Proprioception loss 2

Outcome Breakdown

Outcome Unknown
8 (44.4%)
Ongoing
5 (27.8%)
Recovered/Normal
3 (16.7%)
Died
1 (5.6%)
Euthanized
1 (5.6%)

Emodepside,Praziquantel: lower report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Emodepside,Praziquantel (#1903 of 2,679 by report volume); death-coded 11.1%. PlainBreed drug row · report volume stamp 18 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →